Ann: SIRFLOX ASCO Abstract Released, page-58

Has anyone considered the current situation that has now arisen?

1. We now have confirmation of statistically significant PFS in the liver when SIRT is used.
2. The results confirmed no additional toxicity.
3. Treatment is relatively cheap

Given that there is no confirmation with regard to OS benefit for another two years as an oncologist what do you do with the above information?

Furthermore I still believe strongly that in the case of mCRC where the cancer has only metastasised to the liver front line treatment in these cases will be warranted.

Just my opinion.